NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Finnrick
Free Test

Vendor Intelligence Report: LP Peptide

Published 11 Nov 2026. 34-page investigative report on who is behind LP Peptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across the supplied Finnrick aggregate — 84 tests, 39 pass / 44 fail — LP Peptide’s overall pass rate is 46%. The record is uneven rather than uniformly unusable: GHK-Cu is the relative bright spot, Tirzepatide is mixed, Retatrutide carries the largest failure burden, and Tesamorelin is the clearest poor multi-test signal. Under stricter grading, even the better products compress, making exact-lot verification central.

The public accountability layer is thin. The March 2026 domain, generic terms, unpublished About/Privacy/Careers pages and scoped registry checks did not identify an owner, legal seller, warehouse operator, merchant of record, refund counterparty, or the people making sourcing, QA and batch-release decisions. That is a transparency limitation, not proof that competent personnel do not exist.

Beyond the numbers, the report maps a repeated storefront package: AGO Research and TSLpeptide carry matching catalog/theme evidence, LP Peptide product handles and supply-model copy, while a Yuan Peptide PDF underlies much of the catalog and tracks LP pricing closely. LP also publishes a COA library, but the certificates lack lab attribution/accreditation and do not match to a shippable vial before payment. Lookalike domains, crypto-only checkout, a commission affiliate program without visible disclosure rules and unreconciled review metrics round out the buyer-risk picture.

Inside the full report:

  • Per-product pass/fail trajectories and methodology-divergence charts for all eight tested products
  • RDAP, Wayback and storefront-API chronology from registration through warehouse-model redesign
  • Shared-build analysis linking LP Peptide, AGO Research, TSLpeptide, Defacto pages and lookalike domains
  • Yuan Peptide catalog crosswalk with SKU overlap and price tracking
  • COA register for the 24 certificates, with lab, accreditation, method and lot-match gaps flagged
  • Payment, shipping, affiliate and review-metric exhibits, including crypto checkout and the RT10 count mismatch

Risk assessment

  • Retatrutide quality risk — high: Retatrutide has 33 tests, 18 pass / 15 fail and a 58.12% Finnrick rating; flagship GLP-1 should require exact-lot independent testing.
  • Tesamorelin quality risk — high: Tesamorelin has 14 tests, 5 pass / 9 fail and a 41.47% rating; poor choice absent fresh exact-lot evidence.
  • NAD+ quality risk — high: NAD+ has 3 tests, 0 pass / 3 fail and a 20.37% rating; no positive independent signal.
  • Tirzepatide quality risk — medium: Tirzepatide is mixed at 13 tests, 7 pass / 6 fail and 64.52%; lot verification remains necessary.
  • GHK-Cu quality risk — medium: GHK-Cu is LP Peptide’s relative bright spot at 11 tests, 7 pass / 4 fail and 74.92%, but four failures remain material.
  • BPC-157 quality risk — medium: BPC-157 has 5 tests, 2 pass / 3 fail and 48.11%; the small record deteriorated with added failures.
  • CJC-1295 and MOTS-c quality risk — medium: CJC-1295 and MOTS-c each have 2 tests and 0 passes; sample sizes are small but buyer signal is negative.
  • Counterparty and recourse opacity risk — high: No disclosed legal entity, owner, address or merchant of record; checkout is crypto-only with a $199 minimum and no published refund policy.
  • COA and lot-traceability risk — high: LP Peptide publishes 24 COAs, but they lack a named lab/accreditation and product pages do not expose shippable lot numbers.
  • Brand-authentication and lookalike-domain risk — medium: lppeptide-au.com and lp-peptide.com create name confusion; LP Peptide publishes no authorized-channel list, signed COA lookup or anti-counterfeit system.
  • Factory-direct / multi-brand catalog risk — medium: Yuan catalog links and identical AGO Research/TSLpeptide storefronts undermine the no-reseller-layer claim.
  • Affiliate-promotion disclosure risk — medium: Affiliate terms pay 10% and omit disclosure obligations; one referral-code X placement lacked clear disclosure.
  • Human-use and regulatory-claim risk — medium: Research-use disclaimers coexist with dosing/reconstitution tools and GLP-1 claims, raising buyer and compliance risk.
  • Review-metric integrity risk — medium: RT10 shows 5,725 verified buyers while its visible star breakdown totals 1,066; catalog review, stock and sales metrics are not internally reliable.